Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

26.04 +2.95 (+12.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Biotech Breakouts: 3 Stocks With Massive Upside Potential
Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential 
Via MarketBeat
Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook
Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback
One of them is already a leader in the market for weight management drugs, and the other could join this field. 
Via The Motley Fool
Topics ETFs
Viking Short Interest Hits 5-Year High After Weight-Loss Drug Stumble, But Retail Clings To Bullish Mood For Now
Via Stocktwits
Wall Street Defends Viking As Weight Loss Pill Trial Results Trigger Stock Rout; Retail Calls Selloff ‘Unjustified’
Via Stocktwits
Peering Into Viking Therapeutics's Recent Short Interest
 
Via Benzinga
Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.
The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result. 
Via The Motley Fool
Jim Cramer Expects Palantir To Reach New All-Time High
Market analysts and financial commentators provide crucial guidance in the volatile investment landscape. Cramer says no to VKTX, but expects PLTR to go up. 
Via Benzinga
Down 34%, Should You Buy the Dip on Viking Therapeutics?
Viking aims to enter the billion-dollar weight loss drug market. 
Via The Motley Fool
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years
Both companies have made significant progress in recent years. 
Via The Motley Fool
The Problem With Weight Loss Stocks
There are new ways to tackle weight loss, but the stocks leading the way are lagging. 
Via The Motley Fool
Topics Economy
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts
Investment bank analysts up and down Wall Street are pounding the table on these stocks. 
Via The Motley Fool
Why Viking Therapeutics Stock Popped Nearly 4% Today
The company's obesity drug could have more potential than originally believed. 
Via The Motley Fool
Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk)
Druckenmiller's Duquesne Family Office just scooped up a popular weight-loss stock. 
Via The Motley Fool
Topics Economy World Trade
Why Is Viking Therapeutics Stock Crashing, and Is It a Buying Opportunity?
The market for weight loss treatments is growing significantly and is forecast to continue increasing for several years. 
Via The Motley Fool
Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks Slump
Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful test. 
Via Investor's Business Daily
Viking Therapeutics: What's Next?
Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum. 
Via The Motley Fool
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts
These companies aren't performing as badly as their stock-market performances this year suggest. 
Via The Motley Fool
Benzinga Bulls And Bears: Sunrun, Newegg, Walmart — And Powell Offers Rate Cut Hope
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Here's Why Shares in Viking Therapeutics Crashed This Week
The phase 2 trial results for its key drug didn't pan out quite as planned. 
Via The Motley Fool
Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip?
A disappointing result for its oral obesity candidate hammered the stock price. 
Via The Motley Fool
Here's Why Viking Therapeutics Bounced Back Today
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing. 
Via The Motley Fool
Under Pressure: Palantir and Viking Therapeutics Face Investor Scrutiny
The financial markets are a dynamic arena where fortunes can shift rapidly, and the past week has seen two prominent companies, Palantir Technologies Inc. (NYSE: PLTR) and Viking Therapeutics (NASDAQ:... 
Via MarketMinute
Topics Artificial Intelligence
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?
Viking (VKTX) stock plunged 42% after its obesity pill trial. Experts are split: some call it a $129 Strong Buy, others say it's inferior. 
Via Benzinga
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns
San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet... 
Via MarketMinute
Palantir, AMD, Oracle, Viking And Nvidia: Why These 5 Stocks Are On Investors' Radars Today
U.S. stock indices closed mixed on Tuesday, with the Dow Jones Industrial Average edging up 0.02% to 44,922.27. 
Via Benzinga
Topics Stocks
Which stocks are experiencing notable movement on Tuesday?
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'
Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off is excessive. 
Via Benzinga
Tech Stocks Drop, Palantir Plunges Over 8%: What's Moving Markets Tuesday?
Tech stocks pulled back on Tuesday as the absence of fresh bullish catalysts prompted investors to take profits after the recent months-long rally. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.